Compare LYFT Inc (LYFT) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LYFT Inc vs GeneDx Holdings Corp — how do they compare? LYFT Inc trades at $16.16 (market cap $6.11B), while GeneDx Holdings Corp trades at $67.6 (market cap $2.02B). The key difference: LYFT Inc is far larger — about 3× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is more actively traded (734,640 versus 13,504,560). Which is the better fit depends on your goals — on Pluang, investors hold LYFT Inc for 47 Days and GeneDx Holdings Corp for 19 Days on average.
| LYFT | WGS | |
|---|---|---|
Market Cap | $6.11B | $2.02B |
Volume | 13,504,560 | 734,640 |
Sector | Technology | Health |
52-Week High | $24.57 | $167.51 |
52-Week Low | $12.65 | $34.51 |
Typical Hold Time | 47 Days | 19 Days |
Enterprise Value | $5.57B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lyft trades at $15.60, down 1.02% on the day, with a bullish technical outlook supported by moving averages despite recent earnings misses. The company shows strong profitability with 45.52% gross margins and 42.32% net income margin, while recent developments include European expansion and a $272.5M legal settlement. Cash flow has improved significantly, with operating cash flow reaching $1.17B in 2025.
Lyft presents a mixed investment case with attractive valuation metrics (P/E 2.35, P/S 0.96) but faces execution risks from recent earnings misses and competitive pressures. The 36.67% analyst buy rating and $18.07 consensus target suggest moderate upside potential, though regulatory concerns and market volatility remain key risks.
GeneDx Holdings Corp. (WGS) trades at $68.53, down 4.18% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $21.02 million for 2025, though Q2 2026 earnings beat expectations. Revenue growth is positive, but profitability remains a challenge with negative margins. Analyst consensus is strongly bullish with a $81.00 price target, supported by recent product launches and institutional interest.
The outlook hinges on execution toward profitability amid high cash burn. Investment opportunity lies in the genomic testing market expansion and analyst optimism, but risks include sustained losses, competitive pressure, and reliance on financing. The stock's trajectory will depend on achieving projected margin improvements and revenue scalability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
